EULAV Asset Management boosted its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 2.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,300 shares of the medical research company’s stock after buying an additional 1,000 shares during the period. EULAV Asset Management’s holdings in Thermo Fisher Scientific were worth $6,036,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Wilbanks Smith & Thomas Asset Management LLC purchased a new stake in Thermo Fisher Scientific during the first quarter worth $208,000. Legal & General Group Plc increased its position in shares of Thermo Fisher Scientific by 3.9% in the first quarter. Legal & General Group Plc now owns 1,864,050 shares of the medical research company’s stock worth $286,323,000 after buying an additional 69,279 shares in the last quarter. Investec Asset Management PTY Ltd increased its position in shares of Thermo Fisher Scientific by 3.1% in the first quarter. Investec Asset Management PTY Ltd now owns 8,635 shares of the medical research company’s stock worth $1,329,000 after buying an additional 263 shares in the last quarter. SNS Financial Group LLC bought a new position in shares of Thermo Fisher Scientific during the first quarter worth approximately $330,000. Finally, WINTON GROUP Ltd increased its position in shares of Thermo Fisher Scientific by 6,097.0% in the first quarter. WINTON GROUP Ltd now owns 126,171 shares of the medical research company’s stock worth $20,069,000 after buying an additional 124,135 shares in the last quarter. 87.60% of the stock is currently owned by institutional investors.
Shares of Thermo Fisher Scientific Inc (TMO) opened at 172.57 on Friday. The stock has a 50 day moving average of $176.71 and a 200 day moving average of $166.56. The firm has a market cap of $67.32 billion, a price-to-earnings ratio of 30.06 and a beta of 1.06. Thermo Fisher Scientific Inc has a 12 month low of $139.07 and a 12 month high of $182.87.
The business also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.35%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is currently 10.45%.
TRADEMARK VIOLATION NOTICE: This piece was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.com-unik.info/2017/08/19/eulav-asset-management-has-6-04-million-stake-in-thermo-fisher-scientific-inc-tmo-updated-updated.html.
A number of brokerages have commented on TMO. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $197.00 target price on the stock in a research note on Tuesday, August 1st. Deutsche Bank AG set a $200.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Saturday, June 10th. BidaskClub downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Barclays PLC reiterated an “overweight” rating and set a $200.00 price objective (up from $190.00) on shares of Thermo Fisher Scientific in a research note on Monday, July 17th. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $200.00 price objective (up from $195.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 13th. One research analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $188.56.
In other news, CEO Marc N. Casper sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the completion of the sale, the chief executive officer now owns 269,279 shares of the company’s stock, valued at $46,528,718.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction on Monday, June 5th. The stock was sold at an average price of $176.26, for a total transaction of $440,650.00. Following the completion of the transaction, the chief financial officer now directly owns 37,790 shares of the company’s stock, valued at approximately $6,660,865.40. The disclosure for this sale can be found here. Insiders have sold 39,506 shares of company stock valued at $6,834,758 in the last three months. Corporate insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
What are top analysts saying about Thermo Fisher Scientific Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Thermo Fisher Scientific Inc and related companies.